Martin Memorial Health Systems, in collaboration with the Moffitt Cancer Center and M2Gen, announced that it will be taking part in an innovative study that could revolutionize the way cancer is treated.
Total Cancer Care (TCC) is an exciting new program that features state-of-the-art cancer research between Moffitt and affiliated healthcare providers. This collaboration will develop a new research initiative to improve cancer prevention and treatment by using molecular technology to enhance the ability to diagnose and treat patients. “Our vision is to integrate new technologies into the standard of care and improve outcomes of all cancer patients by partnering with outstanding Florida health care institutions,” said Dr. William Dalton, Moffitt President/CEO and Center Director. “We are also looking forward to collaborating with the physicians to increase access to new and improved therapies for cancer.” Technology has recently advanced to the point that researchers can now test each tumor for approximately 30,000 genes, which provide a molecular “fingerprint” unique to each tumor. By studying those unique molecular structures, scientists will someday be able to develop new drug therapies that are personalized for each individual. By studying and comparing patients responses to specific treatments, scientists hope to learn which drugs work best in different patients, enabling them to individualize treatment for patients with various types of cancer. This approach will enhance the likelihood of patient improvement and reduce side-effects.
